Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX/XIAPEX]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe
Phase of Trial: Phase IV
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Dupuytren's contracture
- Focus Therapeutic Use
- Acronyms AA4500 Re-treatment Study
- Sponsors Auxilium Pharmaceuticals; Endotis Pharma
- 15 May 2015 Results published in the Endo Pharmaceuticals media release.
- 16 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Jan 2014 Planned number of patients changed from 100 to 150 as per European Clinical Trials Database record.